South Korea’s biotechnology sector is making headlines today as several leading domestic firms have secured major licensing agreements with global pharmaceutical giants, underscoring the growing international recognition of Korea’s innovative drug-development platforms. According to industry data released on November 17, 2025, ABL Bio has signed a technology-transfer agreement with Eli Lilly for its proprietary “GrabBody” bispecific antibody platform, a deal valued at up to US$2.56 billion. This platform is designed to enhance the precision of therapeutic delivery, particularly by enabling medicines to cross the blood-brain barrier through targeting the IGF1R receptor. The GrabBody-B system is considered a breakthrough in targeted therapy, and its potential applications span multiple therapeutic areas, including neurology and oncology.

ABL Bio’s success is not isolated. The company previously inked a separate 4-trillion-won agreement with GlaxoSmithKline in April 2025 for the same technology, further cementing its position as a leader in platform-based biotechnology. The GrabBody platform’s ability to deliver therapeutics more efficiently and with greater specificity is attracting significant interest from multinational pharmaceutical companies seeking to accelerate their R&D pipelines and reduce development risk.

Another notable deal involves Alteogen, which has built a strong reputation for its subcutaneous-injection platform, ALT-B4. This enzyme-based technology enables the conversion of intravenous drugs into easier-to-administer subcutaneous formulations, a development that can significantly improve patient compliance and reduce healthcare costs. The platform has attracted major licensing agreements, including a US$1.3 billion deal with AstraZeneca’s MedImmune in March 2025 and a US$300 million contract with Japan’s Daiichi Sankyo late last year. These agreements highlight the global demand for technologies that streamline drug delivery and administration, especially in chronic disease management.

LegoChem Biosciences has also expanded its global footprint by transferring its antibody-drug conjugate (ADC) platform and a lead pipeline candidate to Japan’s Ono Pharmaceutical in a deal valued at up to 940 billion won. ADC platforms are increasingly sought after for their ability to deliver potent cytotoxic agents directly to cancer cells, minimizing off-target effects and improving therapeutic outcomes. The deal with Ono Pharmaceutical is expected to accelerate the development and commercialization of novel ADC therapies in Asia and beyond.

Industry analysts emphasize that platform technologies—versatile systems that can be applied across multiple drug pipelines—offer “low risk, high return” potential compared with single drug development. Such platforms require less R&D investment and often secure revenue through early-stage licensing before commercial products reach the market. This trend is attracting new entrants, with Samsung EpiS Holdings launching a subsidiary, EpiS NexLab, to develop its own biotech platforms, including peptide-based technologies.

Despite these successes, experts caution that platform licensing alone will not propel Korean firms into the ranks of global “big pharma.” Blockbuster drugs—those generating more than 1 trillion won in annual revenue—remain the primary driver of long-term corporate valuation. ABL Bio CEO Lee Sang-hoon echoed this view at the BIO International Convention in June, urging Korean companies to pair their platform successes with more aggressive investments in full drug development.

These developments signal a shift in the global pharmaceutical landscape, with Asian biotech platforms increasingly recognized as key drivers of innovation. The trend is likely to accelerate as global pharma companies seek to diversify their R&D portfolios and tap into the region’s growing expertise in biotechnology and drug delivery. For pharmaceutical executives, R&D heads, and technology vendors, the rise of Korean biotech platforms presents new opportunities for collaboration, licensing, and strategic investment in the region.